Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
Acute peripheral neuropathy often does not resolve between cycles of treatment and severity often increases between cycles.
A prescription drug's label AE section is almost entirely based on clinicians' impression of patients' symptoms, not the patients' own reports.
Skin Cancer News
More Skin Cancer Information
This fact sheet offers tips to decrease the risk of malignant melanoma, the fastest growing forms of skin cancer.
This patient fact sheet describes risk factors and preventative measures in skin cancer, malignant melanoma.
This fact sheet helps cancer patients learn what they can do to protect themselves from skin cancer.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Immunotherapy Combinations for Renal Cell Carcinoma Offer Promise, Challenges
- ASCO Updates Metastatic Lung Cancer Therapy Guideline to Include Targeted Agents, Early Palliative Care
- Association of 21-Gene Recurrence Score Assay, Chemo in Early-stage Breast Cancer
- Sonography, MRI Comparable for Cervical Cancer Staging
- In Cutaneous Melanoma, Early Sentinel-Node Biopsy Associated with Poorer Survival
- Molecular Profiles Can be Used for Early Detection for Aggressive Prostate Cancer
- Thyroid Carcinoma Treatment Regimens
- Combining Aromatase Inhibitors, Bisphosphonates May Benefit Women With Breast Cancer
- Severity of Oxaliplatin-induced Neuropathy in Cycle One Predicts Severity, Development of Neurotoxicity
- Better Preoperative Coordination of Care Needed for Patients With Lung Cancer
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- We Can Treat Hodgkin's Lymphoma Like Melanoma?
- Lymphadenectomy Extent During Esophageal Cancer Surgery May Not Impact Survival
- Risk for SNL Positivity Lower in Melanoma with Histologic Regression
- Targeted Therapy Based on Tumor Molecular Profiling May Not Improve Survival
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|